Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-06-12
2007-06-12
Desai, Rita (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C514S342000
Reexamination Certificate
active
10849591
ABSTRACT:
A hydrate of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt, characterized in that it: (i) comprises water in the range of from 0.4 to 2.5% w/w; and (ii) provides an infra red spectrum containing peaks at 1749, 1703, 1645, 1623, 1365 and 736 cm−1; and/or (iii) provides an X-ray powder diffraction (XRPD) pattern substantially as set out in FIG. II and/or (iv) provides a Raman spectrum containing peaks at 3106, 3069, 3002, 2961, 1750, 1718, 1684, 1385, 1335, 1229, 1078, 917, 428 and 349 cm−1and/or (iv) provides a solid-state nuclear magnetic resonance spectrum containing chemical shifts substantially as set out in Table I; a process for the preparation of such a compound, a pharmaceutical composition containing such a compound and the use of such a compound or composition in medicine.
REFERENCES:
patent: 5002953 (1991-03-01), Hindley et al.
patent: 5741803 (1998-04-01), Pool et al.
patent: 5910592 (1999-06-01), Pool et al.
patent: 6288095 (2001-09-01), Hindley et al.
patent: 6664278 (2003-12-01), Sasse et al.
patent: 6806280 (2004-10-01), Blackler et al.
patent: 6815457 (2004-11-01), Blackler et al.
patent: 2002/0099081 (2002-07-01), Blackler et al.
patent: 2002/0133016 (2002-09-01), Lynch et al.
patent: 0 306 228 (1989-08-01), None
patent: 1 468 997 (2004-10-01), None
patent: WO 93/10254 (1993-05-01), None
patent: 94/05659 (1994-03-01), None
patent: WO 94/05669 (1994-03-01), None
patent: WO 95/21603 (1995-08-01), None
patent: WO 95/21608 (1995-08-01), None
patent: WO 94/05659 (1999-03-01), None
patent: WO 99/31093 (1999-06-01), None
patent: WO 00/64892 (2000-11-01), None
patent: WO 00/64893 (2000-11-01), None
patent: WO 00/64896 (2000-11-01), None
patent: WO 02/26737 (2002-04-01), None
patent: WO 04/085435 (2004-10-01), None
patent: WO 05/021541 (2005-03-01), None
Phadnis et al., “Identfication of drugs in pharmaceutical dosage from by X-ray powder diffrectometry”,J. Pharm. Biomed. Analysis, 15: 929-943 (1997).
Chakravarty et al., “Crystal forms of tolbutamide from acetonitrile and 1-octanol:effect of solvent, humidity and compression pressure”.Int. J. Pharmaceutics, 288: 335-348 (2005).
Muzaffar et al., “Polymorphism and drug availability”.J. Pharmacy(Lahore), 1(1): 59-66 (1979).
Jain et al., “Polymorphism in pharmacy”.Indian Drugs, 23(6): 315-329 (1986).
Taday et al., “Using terahertz plus spectroscopy to study the crystalline structure of a drug: A case study of the polymorphs of ranitidine hydrochloride”,J. Pharm. Sci., 92(4): 831-838 (2003).
Otsuka et al., “Effect of polymorphic forms of bulk powders on pharmaceutical properties of carbamazepine granules”,Chem. Pharm. Bull., 47(6): 852-856 (1999).
E. Doelker. “Séance thermatique. Modification crystallines et transformations polymorphs au cours des operations galeniques”.Ann. Pharm. Fr., 60: 161-176 (2002).
Brittain et al., “Polymorphism in pharmaceutical solids”. NY: Marcel Dekker, Inc., 1999, pp. 125-181, 183-226, 228-330 and 331-361.
Office Action: U.S. Appl. No. 09/581,816, Dec. 4, 2000.
Office Action: U.S. Appl. No. 09/581,816, Aug. 10, 2001.
Office Action: U.S. Appl. No. 10/071,339, Jul. 30, 2002.
Office Action: U.S. Appl. No. 10/354,365, Feb. 17, 2005.
Office Action: U.S. Appl. No. 09/581,719, Mar. 30, 2001.
Office Action: U.S. Appl. No. 10/072,096, Mar. 5, 2003.
Office Action: U.S. Appl. No. 10/030,323, Mar. 5, 2003.
Office Action: U.S. Appl. No. 10/048,123, Jun. 3, 2003.
Office Action: U.S. Appl. No. 10/048,123, Oct. 3, 2003.
Office Action: U.S. Appl. No. 10/030,877, Jul. 11, 2003.
Office Action: U.S. Appl. No. 10/030,877, Nov. 12, 2003.
Office Action: U.S. Appl. No. 10/843,741, Apr. 26, 2005.
Chemical & Engineering News, pp. 32-35 (Feb. 2003).
U.S. Pharmacopia, #23, pp. 1834-1844 (1995).
Concise Encyclopedia Chemistry, pp. 872-873 (1993).
Cantello et al., “Facile Biocatalytic Reduction of the Carbon-Carbon Double Bond of 5-Benzylidenethiazolidine-2,4-diones. Synthesis of (+)-5-[4-[2-methyl(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (BRL 49653), its (R)-(+)-Enantiomer and Analogues”.J. Chem. Soc., Perkin Trans. I, pp. 3319-3324 (1994).
Cantello et al., “The Synthesis of BRL 49653 — A Novel and Potent Antihyperglycaemic Agent”,Bioorg.&Med. Chem. Lett.,4(10): 1181-1184 (1994).
Haleblian et al., “Pharmaceutical Applications of Polymorphism”.J. Pharm., Sci., 58 (8): 911-929 (1969).
The American Heritage Dictionary of the English Language: Fourth Edition. 2000. http://www.bartleby.com/61/32/10253200.html.
Blackler Paul David James
Lee David C
Sasse Michael John
Desai Rita
Kinzig Charles M.
McCarthy Mary E.
Sieburth Kathryn L.
SmithKline Beecham p.l.c.
LandOfFree
5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3850098